Decreased NO production in endothelial cells exposed to plasma from ME/CFS patients.
Bertinat, Romina, Villalobos-Labra, Roberto, Hofmann, Lidija et al. · Vascular pharmacology · 2022 · DOI
Quick Summary
This study looked at how blood from ME/CFS patients affects the inner lining of blood vessels in a laboratory setting. Researchers found that blood vessels exposed to ME/CFS patient blood produced less of a substance called nitric oxide, which is important for healthy blood vessel function. This suggests that problems with blood vessel health in ME/CFS patients may involve reduced nitric oxide production.
Why It Matters
Endothelial dysfunction has been observed in some ME/CFS patients and may contribute to symptoms like fatigue and exercise intolerance. This research identifies a specific molecular mechanism—reduced nitric oxide production—that could underlie blood vessel dysfunction in ME/CFS, potentially opening new avenues for understanding disease pathophysiology and developing targeted treatments.
Observed Findings
HUVECs exposed to ME/CFS-plasma produced significantly less nitric oxide than those exposed to healthy control plasma
Nitric oxide deficiency occurred both at baseline and when cells were stimulated with eNOS-activating compounds
GPCR agonists (bradykinin, histamine, acetylcholine) induced greater NO production deficits than TKR agonist (insulin) in ME/CFS-plasma conditions
Inhibitory eNOS phosphorylation at Thr495 was elevated in ME/CFS-plasma-treated cells compared to control-plasma-treated cells
Inferred Conclusions
ME/CFS patient plasma contains factors that impair eNOS-mediated nitric oxide production in endothelial cells
eNOS dysfunction may represent a previously unrecognized component of endothelial dysfunction in ME/CFS
The preferential impairment of GPCR-mediated signaling suggests a specific disruption in certain endothelial activation pathways in ME/CFS
Remaining Questions
What specific molecular factors or circulating markers in ME/CFS plasma are responsible for reducing eNOS activity?
Does reduced nitric oxide production occur in blood vessels of ME/CFS patients in vivo, and does it correlate with symptom severity?
How does this endothelial dysfunction relate to other proposed mechanisms in ME/CFS, such as immune activation or mitochondrial dysfunction?
What This Study Does Not Prove
This laboratory study does not prove that the identified nitric oxide deficiency occurs in patients' bodies or causes ME/CFS symptoms. Because the study uses plasma components in cell culture rather than intact living systems, it cannot establish causation or determine whether this mechanism is primary or secondary to other disease processes. The findings require validation in larger patient cohorts and in vivo studies.